1-6 of 6
Howard S. Hochster
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6408: Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2

Sara Lonardi, Arvind Dasari, Rocio Garcia-Carbonero, Takayuki Yoshino, Pilar García-Alfonso, Judit Kocsis, Chiara Cremolini, François Ghiringhelli, Ardaman Shergill, Howard S Hochster, Michel Ducreux, Dirk Arnold, Varsha Sundaresan, Siddha Kasar, Adela Pina, Ziji Yu, William R Schelman, Lucy Chen, Josep Tabernero
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6408.
https://doi.org/10.1158/1538-7445.AM2024-6408
Published: 22 March 2024
View article titled, Abstract 6408: Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2
Journal Articles

Abstract 3285: Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance)

Brendan Guercio, Sui Zhang, Alan P. Venook, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Hanna Sanoff, Michelle R. Mahoney, Bert H. O'Neil, James E. Shaw, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Charles S. Fuchs, Jeffrey A. Meyerhardt
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3285.
https://doi.org/10.1158/1538-7445.AM2019-3285
Published: 01 July 2019
View article titled, Abstract 3285: Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance)
Journal Articles

Abstract CT062: A phase I dose escalation study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced gastrointestinal (GI) tumors

Anna M. Varghese, Dana B. Cardin, Jon Hersch, Al B. Benson, Howard S. Hochster, Robert Winkler, Fabio Benedetti, Kensuke Hamada, Jordan D. Berlin, Leonard Saltz
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT062.
https://doi.org/10.1158/1538-7445.AM2018-CT062
Published: 01 July 2018
View article titled, Abstract CT062: A phase I dose escalation study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) in patients with advanced gastrointestinal (GI) tumors
Journal Articles

Abstract A72: Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo + nab-P in arm A

Howard S. Hochster, Zev A. Wainberg, Martin Gutierrez, David Waterhouse, E Gabriela Chiorean, Ben George, Amy Ko, Victoria Manax, Sotirios Stergiopoulos, Peter O'Dwyer
Journal: Cancer Research
Cancer Res (2016) 76 (24_Supplement): A72.
https://doi.org/10.1158/1538-7445.PANCA16-A72
Published: 14 December 2016
View article titled, Abstract A72: Phase 1 study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (G) in pancreatic cancer (PC): safety evaluation of patients treated with nivo + nab-P in arm A
Journal Articles

Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

Jeffrey Wallin, Michael J. Pishvaian, Genevive Hernandez, Mahesh Yadav, Suchit Jhunjhunwala, Lelia Delamarre, Xian He, John Powderly, Christopher Lieu, S Gail Eckhardt, Herbert Hurwitz, Howard S. Hochster, Janet Murphy, Vincent Leveque, Edward Cha, Roel Funke, Daniel Waterkamp, Priti Hegde, Johanna Bendell
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2651.
https://doi.org/10.1158/1538-7445.AM2016-2651
Published: 15 July 2016
View article titled, Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma
Journal Articles

Phase I Trial of Escalating Dose Doxorubicin Administered Concurrently with α2-Interferon

Michael David Green, James Leonard Speyer, Howard S. Hochster, Leonard F. Liebes, Susan Dunleavy, Tova Widman, James Carter Wernz, Ronald Howard Blum, Robert Jay Spiegel, Franco Mario Muggia
Journal: Cancer Research
Cancer Res (1988) 48 (9): 2574–2578.
Published: 01 May 1988
View article titled, Phase I Trial of Escalating Dose Doxorubicin Administered Concurrently with α<sub>2</sub>-Interferon
Open the PDF for Phase I Trial of Escalating Dose Doxorubicin Administered Concurrently with α<sub>2</sub>-Interferon in another window